Compare Charles River Laboratories Intl. Inc (CRL) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Firy Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Firy Inc. trades at $12.07 (market cap $199.80M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 71.2× Firy Inc.'s market cap, and Firy Inc. is more actively traded (92,993 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Firy Inc. for 13 Days on average.
| CRL | FIRY | |
|---|---|---|
Market Cap | $14.23B | $199.80M |
Volume | 1,176,885 | 92,993 |
Sector | Health | Technology |
52-Week High | $310.77 | $13.10 |
52-Week Low | $149.93 | $2.28 |
Typical Hold Time | 33 Days | 13 Days |
Enterprise Value | $17.06B | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
FIRY trades at $12.07, up 1.86% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but a net loss, continuing a trend of negative profitability. Recent developments include a major legal victory with a $719 million judgment and the appointment of Marc Lasry to the board, signaling strategic shifts under its new holding company structure.
The outlook remains challenged by persistent cash burn and negative margins, though the legal win offers potential upside. Risks include high cash outflow and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, reflecting uncertainty around the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
